Viracta Therapeutics, Inc. Profile Avatar - Palmy Investing

Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase…

Biotechnology
US, Cardiff-by-the-Sea [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of VIRX's Analysis
CIK: 1061027 CUSIP: 92765F108 ISIN: US92765F1084 LEI: - UEI: -
Secondary Listings
VIRX has no secondary listings inside our databases.